Literature DB >> 26096363

Hsa-miR-132 inhibits proliferation of hepatic carcinoma cells by targeting YAP.

Chang-Jiang Lei1, Lei Li1, Xia Gao2, Jun Zhang3, Qing-Yun Pan4, Hao-Cheng Long1, Chun-Zhou Chen1, De-Fa Ren1, Gang Zheng1.   

Abstract

MicroRNAs and Yes-associated protein (YAP) play an important role in the occurrence and development of hepatic carcinomas. However, the interaction between microRNAs and YAP was seldom elucidated. In this study, we showed that miR-132 could target YAP gene by using dual-luciferase reporter system. Further quantitative polymerase chain reaction analysis and western blotting showed that miR-132 could significantly reduce the expression of YAP at mRNA and protein levels. Results of annexin V-fluorescein isothiocyanate, 5-ethynyl-2'-deoxyuridine staining and transwell assays showed that miR-132 significantly promoted the cell apoptosis and effectively inhibited the proliferation and invasion of hepatoma cells. These results indicated that miR-132 could inhibit the growth of hepatoma cells by targeting YAP gene and reducing its expression level. Taken together, results from this study would help us to understand the mechanisms for occurrence and development of hepatic carcinoma and provide new targets for diagnosis and treatment of liver cancer.
Copyright © 2015 John Wiley & Sons, Ltd.

Entities:  

Keywords:  Hsa-miR-132; YAP; hepatic carcinoma cells; microRNA

Mesh:

Substances:

Year:  2015        PMID: 26096363     DOI: 10.1002/cbf.3119

Source DB:  PubMed          Journal:  Cell Biochem Funct        ISSN: 0263-6484            Impact factor:   3.685


  13 in total

Review 1.  The outstanding role of miR-132-3p in carcinogenesis of solid tumors.

Authors:  Milad Rafat; Mahta Moraghebi; Masoumeh Afsa; Kianoosh Malekzadeh
Journal:  Hum Cell       Date:  2021-05-17       Impact factor: 4.174

2.  MicroRNA-132 suppresses cell proliferation in human breast cancer by directly targeting FOXA1.

Authors:  Dan Wang; Jin Ren; Hui Ren; Jin-Ling Fu; Dan Yu
Journal:  Acta Pharmacol Sin       Date:  2017-08-17       Impact factor: 6.150

Review 3.  A time for YAP1: Tumorigenesis, immunosuppression and targeted therapy.

Authors:  Masahiro Shibata; Kendall Ham; Mohammad Obaidul Hoque
Journal:  Int J Cancer       Date:  2018-07-24       Impact factor: 7.396

4.  miR-132 inhibits lung cancer cell migration and invasion by targeting SOX4.

Authors:  Yang Li; Lingling Zu; Yuli Wang; Min Wang; Peirui Chen; Qinghua Zhou
Journal:  J Thorac Dis       Date:  2015-09       Impact factor: 2.895

5.  Circulating miR-132-3p as a Candidate Diagnostic Biomarker for Malignant Mesothelioma.

Authors:  Daniel G Weber; Katarzyna Gawrych; Swaantje Casjens; Alexander Brik; Martin Lehnert; Dirk Taeger; Beate Pesch; Jens Kollmeier; Torsten T Bauer; Georg Johnen; Thomas Brüning
Journal:  Dis Markers       Date:  2017-02-21       Impact factor: 3.434

6.  miR-550a-3-5p acts as a tumor suppressor and reverses BRAF inhibitor resistance through the direct targeting of YAP.

Authors:  Min Ho Choe; Yina Yoon; Joon Kim; Sang-Gu Hwang; Young-Hoon Han; Jae-Sung Kim
Journal:  Cell Death Dis       Date:  2018-05-29       Impact factor: 8.469

7.  Oncogenic miR‑132 sustains proliferation and self‑renewal potential by inhibition of polypyrimidine tract‑binding protein 2 in glioblastoma cells.

Authors:  Silong Lou; Jia Ji; Xin Cheng; Jian Ruan; Rong Li; Zhengjun Guo
Journal:  Mol Med Rep       Date:  2017-09-21       Impact factor: 2.952

8.  MicroRNA‑608 sensitizes non‑small cell lung cancer cells to cisplatin by targeting TEAD2.

Authors:  Yanli Wang; Fengcai Li; Dandan Ma; Yuhua Gao; Runpu Li; Yingjie Gao
Journal:  Mol Med Rep       Date:  2019-08-26       Impact factor: 2.952

Review 9.  MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer.

Authors:  Na-Hyun Lee; So Jung Kim; Jeongeun Hyun
Journal:  Biomedicines       Date:  2021-03-30

10.  MicroRNA-132 induces temozolomide resistance and promotes the formation of cancer stem cell phenotypes by targeting tumor suppressor candidate 3 in glioblastoma.

Authors:  Zhen-Xiu Cheng; Wen-Bo Yin; Zhong-Yu Wang
Journal:  Int J Mol Med       Date:  2017-09-07       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.